If a corporation released a new cardiovascular drug it could mean tens of billions of dollars a year, but if instead it was a new innovation for a antibiotic it would be rather saved for the sickest and would not sell nearly as much. Thus the corporations choose to pursue profitable drugs rather than the less profitable antibiotic research. With most corporations choosing this alternative we begin to have a lack of antibiotic research and thus has resulted in the issue we face today. Their are some options one of them results in alliance. If pharmaceutical leaders would gather together and form an alliance of sorts, they could combine there funds, research, and effort into a solution to this crisis thus saving time and money for this crisis. Opportunities in unity like this could drastically shift the tide and provide better incentives for the future of